Menu Search
Equities

Santhera Pharmaceuticals Holding AG

0QN1:LSE

Santhera Pharmaceuticals Holding AG

Actions
  • Price (CHF)9.52
  • Today's Change0.043 / 0.45%
  • Shares traded31.00
  • 1 Year change+41.04%
  • Beta--
Data delayed at least 20 minutes, as of Apr 26 2024 18:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

  • Revenue in CHF (TTM)5.16m
  • Net income in CHF-64.69m
  • Incorporated2002
  • Employees46.00
  • Location
    Santhera Pharmaceuticals Holding AGHohenrainstrasse 24PRATTELN 4133SwitzerlandCHE
  • Phone+41 619068950
  • Fax+41 619068951
  • Websitehttps://www.santhera.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.